title: Resolution of galactomannan antigenemia in a patient receiving oral voriconazole for chronic necrotizing pulmonary aspergillosis.
abstract: The serologic markers of the therapeutic response of chronic necrotizing pulmonary aspergillosis (CNPA) are rarely reported. Here, we describe the changes in galactomannan (GM) antigenemia in a patient receiving oral voriconazole for CNPA, in whom a resolution of GM antigenemia to a normal level was associated with clinical improvements. The serum GM index can be an adjunctive tool for the diagnosis and monitoring of the therapeutic response of CNPA.
authors.affiliation: Division of Clinical Research/Infectious Diseases, National Health Research Institutes, Zhunan, Miaoli County 350, Taiwan.
authors.forename: Chi-Jung
authors.initials: CJ
authors.lastname: Wu
authors.forename: Hsin-Chun
authors.initials: HC
authors.lastname: Lee
authors.forename: Hsiu-Jung
authors.initials: HJ
authors.lastname: Lo
authors.forename: Wen-Chien
authors.initials: WC
authors.lastname: Ko
mesh_terms: D000935:Antifungal Agents / Q000627:therapeutic use*; D000946:Antigens, Fungal / Q000097:blood*; D016903:Drug Monitoring; D005690:Galactose / Q000031:analogs & derivatives; D006801:Humans; D055744:Invasive Pulmonary Aspergillosis / Q000188:drug therapy*; D008297:Male; D008351:Mannans / Q000097:blood*; D011743:Pyrimidines / Q000627:therapeutic use*; D014230:Triazoles / Q000627:therapeutic use*; D065819:Voriconazole; D055815:Young Adult
chemical_list: D000935:Antifungal Agents; D000946:Antigens, Fungal; D008351:Mannans; D011743:Pyrimidines; D014230:Triazoles; C012990:galactomannan; D065819:Voriconazole; D005690:Galactose